AI Summary & Key Takeaways
AI InsightThe medianoverall response rate was 26.3%.
📌 3 Key Takeaways
Abstract
Background/aim: Carfilzomib (CFZ) is a new-generation proteasome inhibitor with significant activity in relapsed or refractorymultiple myeloma (R/R-MM). We have retrospectively evaluated R/R-MM patients who were treated with CFZ plus dexamethasone.Materials and methods: Twenty-one R/R-MM patients who were treated with CFZ plus dexamethasone between October 2013 andJanuary 2016 were screened. The patients were followed until March 2016 after CFZ treatment.Results: Ten (47.6%) of the patients were female and 11 (52.4%) of them were male. The median age was 62 (47–76) years. The mediannumber of prior treatment lines was 3 (2–7). The median number of administered cycles of treatment for CFZ was 4 (1–10). The medianoverall response rate was 26.3%. The most common hematological adverse events were anemia and thrombocytopenia (38%). The mostcommon nonhematological adverse event was fatigue (71.4%). One patient died because of a cerebrovascular event and 1 patient diedbecause of pneumonia during the treatment period. The median duration of response rate and time to next therapy were 8 (7–9) and 3(2–16) months, respectively. The median overall survival was 8 (0.5–33) months.Conclusion: Despite the small number of patients, our results suggest that CFZ provides acceptable responses in heavily pretreatedR/R-MM patients.